Best of the Blog: IN VIVO, April 2009
Executive Summary
A selection of our favorite blog posts from April 2009 for stories not covered elsewhere in this month's IN VIVO. (See them for free at http://invivoblog.blogspot.com/).
You may also be interested in...
Troubled Biotechs (UK Edition): Summit, Alizyme, ReNeuron
More than a third of UK biotechs are short of cash, and those that haven’t already found creative means of monetizing their assets have run out of time.
BMS's Rebloyzl Data Supports Adding Less Severe Patients To Label
Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.
Doctors Frustrated By Lack Of Guidance On Who Should Get Aduhelm
Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.